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The initial studies in Europe with tissue-type plasmin-
ogen activator (rt-PA) have been coordinated by a Eu-
ropean Cooperative Study Group. By February 1987,
258 patients had been entered into comparative coronary
patency trials of rt-PA versus streptokinase and rt-PA
versus placebo (trials completed and published); 123 pa-
tients had entered a coronary patency trial of prolonged
rt ·PA infusion vers us short-ter m rt-PA infusion (t r ial
completed but results not yet published) : and > 500 pa-
tients had been recruited for left vent r icula r function
and infarct size trials comparing rt·PA with placebo and
rt -PA alone with rt-PA plus immediate coronary anglo-
plasty (studies still in progress).
The first three stud ies used two chain rt-PA. 0.75
mg/kg , for the rt -PA versus streptokinase and rt-PA
vers us placebo studies and 40 or 80 mg for the shor t-
term versus long-term study. The current studies are us-
The purpose of this article is to give an overview of past
and current studies with intravenous human recombinant
tissue-type plasminogen activator (rt-PA) in acute myo-
cardia l infarction conducted under the supervision of the
European Coo perative Stud y Gro up. It will discuss the or-
ganization and design of these trials with particular emphas is
on similarities to and differences from contemporary studies
in the United States; it will review the results of trials cur-
rently completed and the side effects and problems. part ic-
ularly in respect to hemorrhagic complications and their
relation to rt-PA dosage .
The European Cooperative Study Group
Plasminogen activator became avai lable in Europe for
clin ical trials in acute myocard ial infarction in early 1984.
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ing single chain rt-Pa in a dose of 100 mg (20 mg bolus,
40,20 and 20 mg in succeeding hours) . Coronary patency
at angiography 90 minutes after the sta rt of treatment
was 70 % for rt-PA and 55 % for st reptokinase. 1.5 mil-
lion units, in the plasminogen activator versus strepto-
kinase study tp = 0.054), 61% for rt-PA and 21% for
placebo in the rt-Pa vers us placebo study (p < 0.001) .
In th e first three studies (251 patient s allocated to rt-
I)A) there was one case of retroperitoneal hematoma.
one of hematemesis and no cases of cerebra l hemor-
rhage; .' 8 patients (15% ) had a hematoma or bleeding
related to arterial catheterization. In the current studies
(439 patients randomized, 334 record s received) two cases
of cerebral hemorrhage (one death ). nin e rases of gas-
troint estinal bleeding and two cases of intraperitoneal
hemorrhage (two deaths) hav e been reported.
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by agreement between Genentech Inc . and Boehringer In-
gelhcim GmbH. The Euro pean Coo perative Study Group
was set up under the chairmanship of M. Verstraete (Leu-
ve ri) to supervise and coo rdinate the studies . To date (March
1987) the following trials have been conducted under the
supervision of the cooperative study gro up:
I ) A coronary patency study com paring intravenous rt -
PA with intravenous streptokinase ( I ).
2) A coronary patency study comparing intravenous rt -
PA with placebo (2) .
3) A coro nary patenc y study comparing short-term rt-PA
infusion with prolonged infusion. with regard tn both initial
patency and reocclusion.
4) A comparison between intravenous rt-PA and placebo,
with angiographic left ventricular function and enzymatic
infarct size as end points .
5) A comparison between intravenous rt-PA alone and
intravenous rt-PA plus immediate coronary angioplasty, with
left ventricular function. infarct size and quantitative ste-
nosis analysis as end points.
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ECSG Stenosis Grade
Table I. Compar ison of Angiographic Criteria in TIMI and
European Cooperative Stul!y Gro up (ECSG) Trials
3 Fut] perfusion
2 Partial perfusion
I Penetration without perfusion
o K0 perfusion
o No stenosis
I <SOCk Stenosis
2 50%< Stenosis < <.)oo/c
3 Stenosis > lJ()'?{ but vessel fills completely within three
cardiac cycles
4 Stenosis > \.)0%. vessel not filling within three cycles
5 Complete occlusion
Characteristic
T[:vtl Perfusion Grade
Design of' the study (l ), The principal differences from
the Thrombolysis in Myocardial Infarction (TIMl) phase I
study (4) were the single blind trial design, absence of
pretreatment angiography and different rt-PA dose schedule.
A single blinddesign was chosen for simplicity and because
it was thought that the facial flushing that often accompanies
streptokinase infusion would in practice identify the patients
receiving this drug. The possibility of pretreatment angi-
ography was discussed but rejected because of the extra
delay it might introduce and the potentially deleterious effect
of this on left ventricular function (5). On the other hand,
the study was designed to be " paired" with a placebo-
controlled study that would give an estimate of spontaneous
patency rates. The choice of 90 minutes for the time of
angiographic assessment was a compromise: earlier angi-
ography would give a better chance of accelerating coronary
perfusion with mechanical (catheter) perforation and angio-
plasty but might have been difficultto achieve for all patients
in all hospitals. Conversely, later angiography might show
a higher patency rate (and a higher spontaneous reperfusion
rate) but might be less relevant to myocardial salvage.
Grading of coronary patency and perfusion. Angie-
graphic coronary patency was assessed centrally by an in-
dependent assessment group. In the absence of pretreatment
angiography, the "infarct-related vessel" was identified with
the aid of the ECG and from the coronary morphology it
was nearly always possible to say whether the vessel in the
infarct related territory was patent. The criteria for coronary
perfusion in the first two studies (1,2) differed from those
in the TIMI study (Tahle I), partly because the European
study did not have the benefit of pretreatment angiography,
partly because the TIMI criteria were then unpublished. We
have subsequently compared the European and TIMI criteria
in >300 patients and found them to be virtually equivalent
in patients with a fully perfused vessel (European stenosis
grade 0-3, TIMI perfusion grade 3). A small proportion of
Grade
Because each of these studies has had its own rationale
and its own set of design and execution problems, they are
described individually here. However, complications, and
especially bleeding complications, are more appropriately
discussed in the context of the combined results from all
the studies.
Certain central organizational featu res have been C01/1-
mon to all the European studies:
I) The studies have been designed and coordinated by a
small steering committee, with responsibility for specific
functions delegated to subcommittees.
2) An independent data collecting center (Stichting Car-
dialysis. Rotterdam) has been responsihle for designing and
issuing record forms, day to day administration of the trial
and collecting and analyzing data. All randomization has
been by telephone call to a dedicated randomization center
in the Netherlands. Funding has been provided by Boeh-
ringer Ingelheim International GmbH.
3) All participating centers have had to satisfy their in-
stitutional research ethics committees concerning partici-
pation in the studies. In addition, an independent review
committee was set up at the outset to advise on ethical issues
and monitor the conduct of the trials.
4) All studies have been designed as " core protocols"
around which individual units may plan further studies. It
is European Cooperative Study Group policy that trial results
will not be disclosed by individuals before definitive col-
lective publication.
Tissue Plasminogen Activator (rt-PA)
Versus Streptokinase
Planning for this study started in March 1984, recruiting
commenced in June 1984and results were published in April
1985 ( I). It was a single blind coronary patency trial of
intravenous rt-PA, 0.75 mgi kg (double chain form), given
over 90 minutes versus intravenous streptokinase, 1.5 mil-
lion units, over 60 minutes. Both patient groups received
heparin. 5000 units, at the start of the infusion; in addition
the streptokinase group received methylprednisolone. 500
mg, and aspirin, 500 mg intravenous (3). The end point
was coronary patency on angiography at 90 minutes after
the start of treatment. Patients were aged 21 to 70 years
with clinical and electrocardiographic (ECG) features of a
first myocardial infarction, symptoms of < 6 hours' dura-
tion , and no contraindications to thrombolytic therapy. Sixty-
four patients were allocated to rt-PA treatment and 70% had
a patent infarct-related vessel: 65 were allocated to strep-
tokinase therapy and 55% had a patent infarct-related vessel
(p = Il.(54 ). The mean time from onset of symptoms to
the start of treatment was 3 hours in the rt-PA group and
2.9 hours in the streptokinase group.
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patients would be regarded as having patent vessels ac-
cording to the European criteria but only partial perfusion
by the TlMI criteria and. conversely. a few patients would
be " fully perfused" by TIMI criteria but not by the Eu-
ropean standards, European stenosis grade 4 overlaps TIMI
perfus ion grades I and 2. but this grade was not regarded
as indicating adequate perfusion in the European studies.
For the sake of comparability, current European trials are
using TIM I perfusion criteria. In retrospect. the absence or
pretreatment angiography probably reduced the abilitv of
the European Cooperative Study Group trial to discrimi'nate
between rt-PA and streptokinase: on the other hand. its
design is probably a better model for subsequent studies
aimed at showing differences in mortality and len ventric-
ular function.
Plasminogen Activator Versus Placebo
This was a double blind comparison of rt-PA versus
placebo with the same entry criteria. dose of rt-PA and mode
of assessment as in the rt-PA-streptokinase study. but car-
ried out in a separate group of seven centers (2). Sixty-four
patients were allocated to treatment with rt-PA and 65 to
placebo. Thirty-eight of 62 assessable coronary angiograms
in the n-PA group showed patent vessels (61%1 as did 13
of 62 angiogram» in the placebo group (21(;lC) tp < 0.0001).
This study confi rmed the "spontaneous" patency rate of
approximately 20% anticipated from previous trials. The
patients in this study and in the rt-Pzv- streptokinasc study
were compared in detail to determine whether any consistent
difference could account for the difference in the rt-PA
perfusion rates in the two studies (70 versus 61 (k). but no
plausible explanation has emerged. This emphasizes the
difficulty and danger of comparing crude perfusion rates
among different trials studying relatively small numbers of
patients .
Short-Term Versus Long-Term rt-PA Infusion
One hundred twenty-three patients entered a study de-
signed to investigate whether a prolonged low dose ;t-PA
infusion would reduce the risk of early reocclusion. Entry
criteria were similar to those of the preceding studies hut
patients with a previous infarct in a different ECG site were
not excluded. All patients received 40 mg n-PA over 90
minutes and then had coronary angiography. Patients with
adequately perfused vessels were randomized to receive either
heparin alone (1.000 units/h) or heparin plus a further 40
mg rt-PA over 6 hours. Angiography was performed again
~ to 24 hours after entry and again at the time of hospital
discharge. Quantitative stenosis analysis was used to de-
termine changes in the caliber of residual stenoses. This
trial has been completed but the result, arc not vet defini-
tively published. •
Left Ventricular Function: rt-PA Versus
Placebo Stud)'
This currently recruiting double blind study compares
left ventricular function and enzymatic infarct size in pa-
tients with acute myocardial infarction of < 5 hours' duration
randomized to either intravenous I1-PA (20 ma bolus. 40.
20. 20 mg in successive hours) or placebo. ~A I1 patients
subsequently receive anticoagulant therapy with heparin for
2 to 3 days and warfarin and aspirin. Left ventricular func-
tion is measured by cineangiography 10 to 22 days after
admission. The study started recruiting in June Iyg6 and is
still blinded.
rt-PA Plus Immediate Angioplasty Versus
rt-PA Alone
This study compares angiographic left ventricular func-
tion ill I{} 10 22 days ami enzymatic infarct sire in patients
Table 2. Bleed ing Co mplica tions in Europea n Plasminogen Activiltor (rl-PA I Tria ls
Complication
Hematoma
Hleeding at ca theter site
Intracerebral
Gastmimestinal
Retroperitoneal
Hematuria
1:l10lXJ transfusion
lJ' h e
0.75 mg:kg 4111110 m;!
Ino mg. Singk' Chain
Double Chain Double Chain < ~..j Hours :> 24 Hours
( n = J25) ( 11 123) i n 237* ) In Ii{ '* I
24 12 42 25
l) t> 2 1 X
() 0 t
t n ()
\I I I
..j J 11
2 4 X l2
<Numher« ror these two columns are based on the assumption that 50S', of patients 1Il the currcntlv blinded
function-placebo study received rt-Px . The ligures reported are fur all patients for whom records have been
received and will doubtless include patients who developed bleeding a lter reccivinu placebo.
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randomized to either 1) 100 mg rt-PA intravenously fol-
lowed as soon as possible by coronary angioplasty; or 2)
rt-PA alone. In addition, quantitative stenosis analysis is
being used to compare infarct-related stenoses in the groups
withand withoutangioplastyand in patientsbeforeand after
angioplasty and at the time of hospitaldischarge. This study
also started recruiting in June 1986.
Complications and Safety Factors in Patients
Receiving rt-PA
Allergic reactions and immediate hemodynamic side ef-
fects from rt-PA have not been encountered. Reperfusion
arrhythmias have occurred at a rate comparablewith that in
other studies.
The effects of double chain rt-PA infusion at a dose of
0.75 mg/kgon plasmafibrinogen and fibrinogen degradation
products were documented in the reports of the first two
trials (1,2). In summary, most patients showed some re-
duction in plasma fibrinogen to a mean approximately one-
third of the starting level. The fibrinogen level rarely fell
below I gldl. Few patients showed a concomitant rise in
fibrinogen degradation products.
With regard 10 clinically apparent bleeding complica-
tions: I) There were no hemorrhage-related deaths in the
first three studies (1,2,5) (252 patients treated with rt-PA,
dose <80 mg). 2) There have been three hemorrhage-related
deaths in the current studies (334 records; single chain rt-
PA, dose 100 mg). One of these deaths was related to
intracerebral bleeding; two were related to intraperitoneal
hemorrhage and at least one of these was related to trauma
incurred before thrombolytic therapy. 3) There were no
instances of intracerebral hemorrhage in the 252 patients
treated with rt-PA in the first three studies; two instances
have occurred in the current studies. Other clinical mani-
festations of hemorrhage are noted in Table 2.
The 15% incidence rate ofcatheter-related hematoma or
prolonged bleeding in these studies is lower than that re-
ported for the TIMI study (4), but this may reflect differ-
ences in reporting as well as a less prolonged catheter pro-
cedure.
Differences in incidence of hemorrhage may also be due
to theeffectsof agentsother then rt-PA, particularlyheparin,
aspirin and coumarin anticoagulants. In the first two studies
the end point was the 90 minute arteriogram, and clinics
were allowed free scope for anticoagulant regimens there-
after. In the current studies the recommended regimen is
heparin, 1,000 unitslh for 3 days, followed by warfarin.
Aspirin is given as an intravenous loading dose of 250 mg
followed by 75 to 125 mg on alternate days.
Conclusions
The European experiencewith rt-PA in acute myocardial
infarction has in general corroborated and complemented
the experience obtained in the United States and is com-
patible with assessment of the drug as a reasonablyeffective
and relatively safe thrombolytic agent. In retrospect, greater
collaboration in defining criteria, methods and protocols
would have led to greatercomparabilityand less frustration,
but diversity is sometimes the mother of progress. It is now
nearly 5 years since we were enjoined "not to let the genie
out of the bottle"(6). The genie is getting restive, with a
number of clinical trials being set up in Europe outside the
auspices of the European Cooperative Study Group, and a
growing reluctance in some centers to put patients into ran-
domized studies. We must pool our experiences and ensure
that we get the maximal amount of valid information from
our current trials.
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